BioSpace News Archive

Superabsorbent dressings are designed to absorb and retain exudate. Superabsorbent dressings are promoted for use on moderate to highly exudate wounds to absorb and retain fluid, thus reducing the risk of leakage and minimizing the risk of maceration.

Endovenous Cyanoacrylate Glue and Polidocanol Injectable Foam Gain Popularity as Minimally-invasive Treatment Options

Radioimmunoassay (RIA) is an in vitro assay for measuring antibody levels by introducing a radiolabeled antigen and determining the subsequent radioactivity of the antibody component.

With the advent of digitalization, the aesthetic implant market is witnessing significant developments in terms of technology and adoption of new materials.

The trial, part of a collaboration with U.S. government agencies including BARDA, the FDA and the NIH, will evaluate the safety, efficacy and tolerability of the anti-SARS-CoV-2 hyperimmune globulin that, if proven safe and effective, could be a potential treatment for COVID-19

LamPORE is a new, rapid, scalable, accurate test, for the detection of the SARS-CoV-2 virus that causes COVID-19.

Results support clinicaldevelopment of IRAK4-targeted protein degrader in hidradenitis suppurativa (HS)and other IL-1R/TLR-driven autoimmune and inflammatory diseases, with Phase 1 trial on track for start in 2021

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader specializing in blood purification, announced today that the U.S. Army Medical Research Acquisition Activity (USAMRAA), has awarded the Company a two-year SBIR Sequential Phase II contract valued at $1,098,588

Precigen, Inc. (Nasdaq: PGEN), today announced that leading science and technology company and existing shareholder Merck KGaA, Darmstadt, Germany, through its wholly owned subsidiary, Ares Trading S.A., has elected to voluntarily convert a convertible note with an outstanding principal balance of $25 million

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the American College of Rheumatology (“ACR”) has accepted the results from the Company’s second interim analysis of its ongoing NAV3-31 Phase 2b clinical study for presentation at the ACR Annual Meeting